April 18th 2024
Data stems from week 28 results of the German G-EPOSS study evaluating the effectiveness of guselkumab in skin health, quality of life, sexuality, and stigmatization.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Frontline Forum Part 3: Challenges and Opportunities to Enhance Psoriasis Management
A panel of experts discusses tailoring treatment to patient needs, supporting patients' mental health, and considering future directions.
Frontline Forum Part 2: Challenges and Opportunities to Enhance Psoriasis Management
A panel of experts discusses unique needs of patients with skin of color, look at long-term safety and efficacy of emerging oral treatments, and delve into combining topicals with systemic therapies.
Frontline Forum Part 1: Challenges and Opportunities to Enhance Psoriasis Management
A panel of experts discuss navigating regimen complexity, patient-friendly adherence strategies, addressing steroid phobia and attitudes, and dive into current treatment guidelines.